Litigation Details for Amgen Inc. v. Hospira, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Amgen Inc. v. Hospira, Inc. (D. Del. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-02-10 |
Court | District Court, D. Delaware | Date Terminated | 2022-03-21 |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Plaintiff | Referred To | |
Patents | 10,046,031; 10,046,058; 10,047,033; 6,228,398; 8,058,052; 8,105,626; 8,173,158; 8,461,187; 9,000,002; 9,000,011; 9,000,038; 9,022,022; 9,028,005; 9,040,034 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Amgen Inc. v. Hospira, Inc.
Biologic Drugs cited in Amgen Inc. v. Hospira, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Amgen Inc. v. Hospira, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-09-10 | 94 | Redacted Document | and buffers are super pure water, 10:46:31 11 A. This is -- you know, this is really…to in the patent, 09:26:38 5 be relative because they're what the patent is teaching…teaching that the patent, that there's any 09:29:12 15 patent says is there…#x27;707 patent? 11:01:14 18 is used in the claims of the '707 patent? 10:57:56…“Pfizer”) with respect to U.S. Patent No. 8,273,707 (the “’707 Patent”). This is a case arising | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |